Tesamorelin vs Retatrutide: differences, evidence and safety

Answer first

Tesamorelin copies the brain hormone that releases growth hormone and is approved only in the United States, for deep belly fat in adults with HIV. Retatrutide imitates three hormones that govern appetite, insulin and energy use, and is approved nowhere. Tesamorelin trials measured belly fat, retatrutide trials body weight. No study comparing them directly could be found.

At a glance

How they work

The two substances are both peptides made in the laboratory, but they act on entirely different hormone systems.

Tesamorelin

• It is a chain of 44 amino acid building blocks, a full copy of growth hormone releasing hormone. A small six-carbon group (a hexenoyl group) at the front end slows its breakdown ^[1].
• It binds to the docking points for this hormone on the pituitary gland, which then releases growth hormone in its normal pulses ^[1].
• Growth hormone acts partly through IGF-1, a messenger made mainly in the liver. In patients, the treatment raised IGF-1 and its carrier protein IGFBP-3 ^[1].

Retatrutide

• It is a chain of 39 amino acid building blocks with a fatty acid chain attached. The drug company Eli Lilly developed it under the code LY3437943 ^[2].
• A single molecule switches on the docking points, or receptors, for three hormones: GIP, GLP-1 and glucagon. Between them they govern appetite, insulin release and how much energy the body burns ^[2].
• Switching on GLP-1 makes people eat less and slows the stomach down. A dedicated study confirmed that the stomach empties more slowly in people ^[3].
• The glucagon part is meant to raise energy use and change how the liver handles fat ^[2]. A direct measurement of that in people could not be found in the sources behind this page.

The core difference lies in the target. Tesamorelin works one step before growth hormone, in the chain that runs from the brain to the pituitary gland. Retatrutide works on the hormones of eating and blood sugar, and growth hormone plays no part in its design.

Their time in the body differs just as much. Tesamorelin has a half-life of about 11 minutes in healthy adults ^[1]. Retatrutide clings to albumin, a carrier protein in the blood, and the body takes about six days to clear half of it ^[4].

What the studies show

No study that compares tesamorelin and retatrutide directly could be found in the published record reviewed for this page. The two were tested in different people, for different purposes. Tesamorelin trials measured the deep fat around the organs on a scan, in square centimetres or as a percentage change of that fat alone. Retatrutide trials weighed the whole body and reported the percentage change in weight. A per cent of belly fat and a per cent of body weight are different quantities.

Tesamorelin: deep belly fat in adults with HIV

Phase 3 RCT The first approval trial randomised 412 adults with HIV and lipodystrophy, a condition in which body fat is redistributed in an unusual way.

After 26 weeks the deep fat around the organs (visceral fat), measured by scan, had fallen by 15.2 per cent on treatment. It rose by 5.0 per cent on placebo (p < 0.001) ^[5]. The official label reports the same result as a difference of 31 square centimetres, or 20 per cent ^[1].

Phase 3 RCT The second trial followed 404 adults for six months. The deep fat fell by 10.9 per cent on treatment, against 0.6 per cent on placebo (p < 0.0001). Fat on the arms and legs did not change, and neither did the fat just under the skin of the belly ^[6].

Meta-analysis Pooling five randomised trials, the difference against placebo averaged 27.71 square centimetres of visceral fat. Body mass index did not change significantly ^[7].

Retatrutide: body weight in adults with obesity

Phase 2 RCT In a mid-stage trial, 338 adults with obesity were given one of four doses or a dummy injection. After 48 weeks, weight had fallen by 24.2 per cent on the highest dose, against 2.1 per cent on placebo ^[8].

On that dose, 83 per cent of participants lost at least 15 per cent of their body weight, against 2 per cent on placebo ^[8].

Phase 3 (press release only) TRIUMPH-1 followed 2,339 adults without diabetes for 80 weeks. The reported weight loss on the highest dose was 28.3 per cent, against 2.2 per cent on placebo ^[9]. The figure comes from a company press release, not from a scientific journal.

Phase 3 (press release only) TRIUMPH-3 enrolled 1,949 adults with severe obesity and diagnosed heart disease. After 80 weeks the reported weight loss reached 22.6 per cent, against 3.2 per cent on placebo ^[10]. By 6 September 2026 none of the late-stage trials had been published in full.

Body weight: the endpoint the two do not share

Phase 3 RCT Tesamorelin changed where fat sits, not how much a person weighs. Average body weight moved by −0.4 kg in the first approval trial and +0.5 kg in the second, neither different from placebo ^[1].

The label states that the drug is not indicated for weight-loss management, because its effect on weight is neutral ^[1].

Liver fat: measured in both, but differently

RCT For tesamorelin, a trial enrolled 61 people with HIV whose liver fat was at least 5 per cent. After twelve months, that fraction fell by 4.1 percentage points more than on placebo. In relative terms that is a fall of 37 per cent ^[11].

After a year, 35 per cent of the treated group were below the 5 per cent threshold, against 4 per cent on placebo ^[11].

Phase 2a RCT For retatrutide, a planned sub-study enrolled 98 people without diabetes whose livers were at least 10 per cent fat. After 24 weeks, liver fat had dropped by 42.9 per cent on the lowest dose and 82.4 per cent on the highest. It edged up by 0.3 per cent on placebo ^[12].

In the two highest dose groups, 79 per cent and 86 per cent reached a normal liver, below the 5 per cent mark ^[12]. The two liver trials differ in who took part, in how long they ran and in how the change was expressed.

Blood sugar

Phase 2 RCT In 281 adults with type 2 diabetes, retatrutide lowered long-term blood sugar (glycated haemoglobin) after 24 weeks. The fall was 2.02 percentage points on the highest dose, against 0.01 on placebo. An established comparator drug, dulaglutide, lowered it by 1.41 points ^[13].

Phase 2 RCT Tesamorelin was tested in 53 adults who already had type 2 diabetes. Twelve weeks of treatment left the insulin response, fasting glucose and long-term blood sugar where they were ^[14].

Heart events

Phase 3 (press release only) TRIUMPH-3 counted serious heart events for retatrutide. Counted across three kinds of event, the hazard ratio was 1.12, with a range of 0.64 to 1.96 ^[10]. That range takes in no difference at all, so it shows neither a benefit nor a harm.

For tesamorelin, the label states that long-term cardiovascular safety has not been established ^[1]. No trial showing that either substance prevents heart attacks or strokes could be found.

What happens after stopping

Phase 3 RCT In the tesamorelin extension, 263 participants were randomised again for a further 26 weeks. Those who stayed on treatment held the reduction at 18 per cent below their starting point at 52 weeks. Those switched to placebo lost the gains, and the deep fat accumulated again ^[15].

For retatrutide, the longest follow-up that could be found is 104 weeks. That extension was limited to people with a body mass index of at least 35 ^[9]. A trial built to measure heart and kidney outcomes enrols 10,000 people and will not report its main result before February 2029 ^[16].

These results come from different populations, doses, endpoints and study lengths. A fall in visceral fat measured in square centimetres cannot be set against a fall in body weight measured in per cent.

Safety

The two safety records differ in where they come from. Tesamorelin has a current official label drawn from its approval trials. Retatrutide has no approved label, and every safety figure comes from trials run by its manufacturer.

Tesamorelin, from the American label:

• Injection-site reactions in 17 per cent against 6 per cent on placebo over the first 26 weeks, including redness, itching, pain and swelling ^[1].
• Joint pain in 13 per cent against 11 per cent. Muscle pain affected 6 per cent against 2 per cent, and swelling of the ankles and feet 6 per cent against 2 per cent ^[1].
• Higher blood sugar. By week 26, long-term blood sugar had reached 6.5 per cent or more in 5 per cent of those treated, against 1 per cent on placebo. The odds of developing diabetes were raised (odds ratio 3.3; 1.4 to 9.6) ^[1].
• Raised IGF-1. At 26 weeks, 47 per cent of participants were more than two standard deviations above normal. The label calls the long-term consequences unknown ^[1].
• Situations that rule it out entirely: an active cancer, a disrupted link between the hypothalamus and the pituitary gland, a known allergy, and pregnancy ^[1].

Retatrutide, from the trial reports; the TRIUMPH-1 figures come from a company press release:

• Nausea in 42.4 per cent against 14.8 per cent on placebo in the highest-dose group of TRIUMPH-1. Diarrhoea affected 32.0 per cent against 13.5 per cent, and vomiting 25.3 per cent against 4.8 per cent ^[9].
• Odd skin sensations such as tingling, burning or numbness (dysesthesia) affected 12.5 per cent against 0.9 per cent in the same comparison ^[9].
• More people stopped at higher doses. In TRIUMPH-1, 11.3 per cent of the highest-dose group stopped treatment, against 4.9 per cent on placebo ^[9].
• A faster pulse. In the mid-stage obesity trial the rise grew with the dose, peaked at week 24 and then eased ^[8]. An independent assessment puts the largest increase at 6.7 beats per minute ^[17].
• Irregular heartbeat has been flagged. A second independent review lists mild to moderate arrhythmia and calls for long trials that measure what happens to patients ^[18].
• A case outside any trial. A 2026 report describes a man with type 1 diabetes who injected a product bought online under this name. He developed severe vomiting, acid build-up in the blood and sudden kidney damage ^[19].

Material sold as a research peptide carries a separate problem for both substances. Reviews from 2026 place tesamorelin in the unregulated market for research compounds, where composition and purity are unverified ^[20], ^[21].

Why this page lists no doses. Tesamorelin is a prescription medicine, and retatrutide is an investigational drug that no authority has approved. Choosing an amount is a matter for the official product information, the prescribing doctor or a supervised trial. This page therefore reports what the studies measured without repeating the amounts they used.

Legal status

Tesamorelin has been a US prescription medicine since 10 November 2010 and is approved only for excess belly fat in adults with HIV and lipodystrophy ^[22]. Its European application was withdrawn on 21 June 2012, and the Canadian product was cancelled on 30 September 2022 ^[23], ^[24]. Retatrutide is approved in no market; it is an investigational drug in phase 3 ^[25]. Its manufacturer announced a United States filing for early 2027, not made by 6 September 2026 ^[10]. Both are banned in sport at all times. Tesamorelin is named in section S2.2.4 of the 2026 list ^[26]. Retatrutide falls under section S0, which covers substances without any current approval ^[27]. Status: 6 and 7 September 2026.

Used together?

The blend directory lists no product that combines tesamorelin and retatrutide. Tesamorelin appears there only in mixtures with growth hormone peptides, such as Tesamorelin + Ipamorelin. Retatrutide appears in one mixture, Loretta, together with eloralintide. The full list is under blends.

No study of tesamorelin and retatrutide given together could be found in the sources reviewed for this page. The two act on unrelated hormone systems, and no report on what the combination does or how safe it is could be found.

More on both substances is in the monographs on tesamorelin and retatrutide. The rules of sport for both classes are set out under peptides banned in sport.

Frequently asked questions

Which is better, tesamorelin or retatrutide?

Neither can be ranked, because no study comparing them could be found. In adults with HIV and lipodystrophy, tesamorelin reduced deep belly fat by 15.2 per cent over 26 weeks, while it rose by 5.0 per cent on placebo. In adults with obesity, retatrutide lowered body weight by 24.2 per cent over 48 weeks on the highest dose, against 2.1 per cent on placebo. The people, the endpoints and the trial lengths differ too much for a verdict.

Which is better for fat loss, tesamorelin or retatrutide?

That question has no answer from the trials, because the two were tested for different things. Tesamorelin is approved only to reduce excess deep belly fat in adults with HIV and lipodystrophy, and its label states that it is not for weight loss. Retatrutide trials measured body weight in people with obesity, and no authority has approved it for anything.

What is the difference between tesamorelin and retatrutide?

Tesamorelin is a copy of growth hormone releasing hormone and works through the pituitary gland. Retatrutide switches on the docking points for three hormones, GIP, GLP-1 and glucagon, which govern appetite, insulin release and energy use. Tesamorelin has been a prescription medicine in the United States since 2010. Retatrutide is in late-stage trials and is approved in no country.

Is tesamorelin or retatrutide safer?

No study weighing their safety side by side could be found, so no ranking is possible. Tesamorelin has an official label with measured frequencies, such as injection-site reactions in 17 per cent against 6 per cent on placebo and raised odds of diabetes. Retatrutide has no approved label, and its safety figures come from trials run by the manufacturer. The largest, TRIUMPH-1, reported nausea in 42.4 per cent against 14.8 per cent on placebo in a press release.

Can tesamorelin and retatrutide be taken together?

No study of the two given together could be found, so nothing is known about the effect or the safety of the combination. The blend directory lists no product that contains both. They work through unrelated hormone systems, and no label text or trial record describing them combined could be found.

Is tesamorelin a weight-loss drug like retatrutide?

No. The official label of tesamorelin states that it is not indicated for weight-loss management, because its effect on weight is neutral. In its two approval trials average body weight changed by −0.4 kg and +0.5 kg, neither different from placebo. What changed was where the fat sits, not how much a person weighs.

Are tesamorelin and retatrutide approved?

Tesamorelin is approved in the United States only, for excess belly fat in adults with HIV and lipodystrophy. Its European application was withdrawn in 2012. Retatrutide is approved nowhere. Its manufacturer announced a United States filing for early 2027 but had not made one by 6 September 2026.

Are tesamorelin and retatrutide banned in sport?

Yes, both at all times, in competition and out of it, but under different sections. The 2026 prohibited list names tesamorelin in section S2.2.4 among the growth hormone releasing factors. Retatrutide is not named; it falls under section S0, which covers every substance without a current approval by any health authority.